Impax's $20M Settlement In Pay-For-Delay Suit Clears Hurdle

Law360 (April 5, 2018, 8:34 PM EDT) -- A Massachusetts federal judge gave her initial approval Thursday to Impax Laboratories Inc.’s $20 million midtrial settlement with a class of consumers and insurers that claimed the lab delayed the launch of a generic acne medicine in exchange for a $40 million payment.

Pending a fairness hearing where class members can object to the deal, U.S. District Judge Denise J. Casper gave her preliminary approval for the $20 million payout to a settlement fund for consumers and insurers who paid for Solodyn. The suit claimed Impax waited three years to launch its generic version of Solodyn after reaching an agreement in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!